{'fraction_non_alphanumeric': 0.022488755622188907, 'fraction_numerical': 0.0074962518740629685, 'mean_word_length': 4.855263157894737, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Intramedullary Spinal Cord Metastases from Small Cell Lung Cancer: Report of One Case and Review of the Literature


 Purpose

Spinal cord intramedullary metastasis (ISCM) is a rare malignant tumor of the nervous system. Small cell lung cancer (SCLC) accounts for about 15% of lung cancer, and the incidence of brain metastasis is high, but intramedullary spinal cord metastasis is rare. In recent years, the first-line treatment of patients with ISCM from SCLC has been controversial. For these patients with ISCM, the options are usually depending on the progression of the disease.However,the outcom of treatments are not satisfacted.Thus,We try to indentify the use of immunotherapy in ISCM from SCLC.
Methods

In our review, we focused on clinical trials of immunotherapy, especially in relation to ISCM in SCLC.
Results

A patient was diagnosed as ISCM from SCLC. Radiotherapy for ISCM was started on January 11, 2021 Apatinib was taken orally after radiotherapy. The overall survival was almost 8 months, and there was only 1 month after ISCM was diagnosed.
Conclusion

Finding practical treatment options for SCLC is an important goal. Previous trials have shown that immunotherapy with checkpoint inhibitors may be an effective approach for long-term disease control and a new breakthrough in the treatment of ISCM form SCLC.